May 1, 2017 / 12:44 PM / 4 months ago

BRIEF-Bellerophon Therapeutics announces new data from phase 2 study

May 1 (Reuters) - Bellerophon Therapeutics Inc

* Bellerophon therapeutics - announced new data from phase 2 study evaluating use of inopulse in idiopathic pulmonary fibrosis patients with pulmonary hypertension

* Bellerophon therapeutics-data show inopulse associated with clinically meaningful improvements in hemodynamics, exercise capacity in difficult-to-treat ph-ipf patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below